Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Shapiro · SciRah

Researcher profile · Semantic Scholar

G. Shapiro

Share profile

G. Shapiro — researcher profile on SciRah

h-index: 103
Works: 532
Citations: 40K

Most-cited papers

Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
Srivatsan Raghavan, Peter S. Winter, Andrew W. Navia, Hannah L. Williams +43 more
2021Cell503 citations Open access
Semantic Scholar
Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration
A. Drilon, J. Clark, J. Weiss, S. Ou +17 more
2020Nature Medicine362 citations Open access
Semantic Scholar
Targeting replication stress in cancer therapy
A. D. da Costa, Dipanjan Chowdhury, G. Shapiro, A. D'Andrea +1 more
2022Nature reviews. Drug discovery336 citations Open access
Semantic Scholar
A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors
Jia Zhou, C. Gelot, Constantia Pantelidou, Adam Li +10 more
2021Nature Cancer289 citations Open access
Semantic Scholar
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
A. Färkkilä, D. Gulhan, J. Casado, C. Jacobson +23 more
2020Nature Communications256 citations Open access
Semantic Scholar
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer
K. Morel, Anjali V. Sheahan, Deborah L. Burkhart, Sylvan C. Baca +33 more
2021Nature Cancer229 citations Open access
Semantic Scholar
Biomarker-Guided Development of DNA Repair Inhibitors
J. Cleary, Andrew J. Aguirre, G. Shapiro, A. D'Andrea
2020Molecules and Cells212 citations Open access
Semantic Scholar
Crizotinib in Patients With MET-Amplified NSCLC.
D. Camidge, G. Otterson, J. Clark, S. Ignatius Ou +10 more
2021Journal of Thoracic Oncology153 citations Open access
Semantic Scholar
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours
M. Middleton, E. Dean, T. J. Evans, G. Shapiro +5 more
2021British Journal of Cancer113 citations Open access
Semantic Scholar
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
M. Saleh, M. Patel, T. Bauer, S. Goel +15 more
2021Clinical Cancer Research108 citations Open access
Semantic Scholar
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
J. Harding, S. Piha-Paul, Ronak H. Shah, J. Murphy +24 more
2023Nature Communications84 citations Open access
Semantic Scholar
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
K. Do, B. Kochupurakkal, Sarah Kelland, Adrienne de Jonge +9 more
2021Clinical Cancer Research84 citations Open access
Semantic Scholar
FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma
J. Cleary, Srivatsan Raghavan, Qi-Biao Wu, Yvonne Y. Li +36 more
2021Cancer Discovery69 citations Open access
Semantic Scholar
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
H. Mahdi, Navid Hafez, D. Doroshow, D. Sohal +12 more
2021JCO Precision Oncology65 citations Open access
Semantic Scholar
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
G. Shapiro, R. Wesolowski, C. Devoe, S. Lord +6 more
2021British Journal of Cancer63 citations Open access
Semantic Scholar
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
P. Konstantinopoulos, A. D. da Costa, D. Gulhan, Elizabeth K. Lee +15 more
2021Nature Communications58 citations Open access
Semantic Scholar
Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.
Irene Braña, G. Shapiro, M. Johnson, H. Yu +11 more
202158 citations
Semantic Scholar
Targeting DNA repair with combined inhibition of NHEJ and MMEJ induces synthetic lethality in TP53-mutant cancers
Jeffrey Patterson-Fortin, Arindam Bose, Wei-Chih Tsai, Carter Grochala +9 more
2022Cancer Research55 citations Open access
Semantic Scholar
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
F. Batalini, N. Xiong, N. Tayob, M. Polak +11 more
2022Clinical Cancer Research54 citations Open access
Semantic Scholar
Phase II clinical trial of everolimus in a pan-cancer cohort of patients with mTOR pathway alterations
E. Adib, K. Klonowska, K. Giannikou, K. Do +15 more
2021Clinical Cancer Research50 citations Open access
Semantic Scholar
Report of the First International Symposium on NUT Carcinoma
C. French, M. Cheng, G. Hanna, S. DuBois +19 more
2022Clinical Cancer Research49 citations Open access
Semantic Scholar
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
K. Jhaveri, Howard A. Burris, T. Yap, E. Hamilton +7 more
2021Expert Review of Anticancer Therapy49 citations Open access
Semantic Scholar
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study
S. Cousin, J. Blay, I. Garcia, J. S. de Bono +26 more
2021International Journal of Cancer49 citations Open access
Semantic Scholar
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
F. Meric-Bernstam, J. Ford, P. O'Dwyer, G. Shapiro +19 more
2023Clinical Cancer Research48 citations Open access
Semantic Scholar
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
H. Park, G. Shapiro, X. Gao, A. Mahipal +13 more
2022ESMO Open47 citations Open access
Semantic Scholar
MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity
T. Branigan, D. Kozono, Amy E. Schade, Peter Deraska +6 more
2021Cell Reports47 citations Open access
Semantic Scholar
A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
C. Weekes, A. C. Lockhart, P. LoRusso, Elaine Murray +8 more
2020The Oncologist46 citations Open access
Semantic Scholar
Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes
T. Yap, E. Hamilton, T. Bauer, E. Dumbrava +7 more
2022JCO Precision Oncology44 citations Open access
Semantic Scholar
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
Constantia Pantelidou, Heta Jadhav, Aditi Kothari, Renyan Liu +3 more
2021npj Breast Cancer43 citations Open access
Semantic Scholar
Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC)
T. Keenan, Tian-Yu Li, Tuulia Vallius, J. Guerriero +18 more
2020Clinical Cancer Research43 citations Open access
Semantic Scholar
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial
J. Hilton, M. Cristea, S. Postel-Vinay, C. Baldini +18 more
2022Cancers42 citations Open access
Semantic Scholar
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
Elizabeth Pan, Wan-Ling Xie, Archana Ajmera, Arlene Araneta +14 more
2023Molecular Cancer Therapeutics41 citations Open access
Semantic Scholar
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
Lestat R. Ali, A. Garrido-Castro, P. Lenehan, Naima Bollenrucher +6 more
2023Journal of Experimental Medicine40 citations Open access
Semantic Scholar
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
M. Telli, S. Tolaney, G. Shapiro, M. Middleton +14 more
2022npj Breast Cancer38 citations Open access
Semantic Scholar
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
A. Choudhury, C. Higano, J. de Bono, N. Cook +22 more
2022Clinical Cancer Research36 citations Open access
Semantic Scholar
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Joseph W. Kim, R. McKay, M. Radke, Shi-Lin Zhao +20 more
2022Journal of Clinical Oncology35 citations Open access
Semantic Scholar
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer
G. Curigliano, G. Shapiro, R. Kristeleit, A. A. Abdul Razak +15 more
2022British Journal of Cancer35 citations Open access
Semantic Scholar
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas
J. Eder, D. Doroshow, K. Do, V. Keedy +4 more
2021JCO Precision Oncology34 citations Open access
Semantic Scholar
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
E. Swisher, R. Kristeleit, A. Oza, A. Tinker +18 more
2021Gynecologic Oncology33 citations Open access
Semantic Scholar
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors
K. Do, Claire Manuszak, Emily M. Thrash, A. Giobbie-Hurder +6 more
2021Cancer Immunology and Immunotherapy33 citations
Semantic Scholar
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
P. Konstantinopoulos, Su-Chun Cheng, J. Supko, M. Polak +19 more
2021British Journal of Cancer33 citations Open access
Semantic Scholar
MUC1-C DICTATES PBRM1-MEDIATED CHRONIC INDUCTION OF INTERFERON SIGNALING, DNA DAMAGE RESISTANCE AND IMMUNOSUPPRESSION IN TRIPLE-NEGATIVE BREAST CANCER
N. Yamashita, Yoshihiro Morimoto, A. Fushimi, R. Ahmad +16 more
2022Molecular Cancer Research29 citations Open access
Semantic Scholar
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
Harshabad Singh, Yvonne Y. Li, L. Spurr, A. Shinagare +26 more
2021Clinical Cancer Research29 citations Open access
Semantic Scholar
RETRACTED ARTICLE: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer
Jeffrey Patterson-Fortin, Heta Jadhav, Constantia Pantelidou, Tin Phan +10 more
2023Nature Communications25 citations Open access
Semantic Scholar
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
R. Plummer, E. Dean, H. Arkenau, C. Redfern +10 more
2021Lung Cancer25 citations Open access
Semantic Scholar
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
W. Tap, Arun S. Singh, S. Anthony, Michael Sterba +20 more
2021Clinical Cancer Research25 citations Open access
Semantic Scholar
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
V. Subbiah, I. Braña, A. Longhi, V. Boni +13 more
2022Clinical Cancer Research24 citations Open access
Semantic Scholar
Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors
M. Gordon, G. Shapiro, J. Sarantopoulos, D. Juric +6 more
2022Frontiers in Oncology23 citations Open access
Semantic Scholar
Pharmacokinetics and Safety of PTC596, a Novel Tubulin‐Binding Agent, in Subjects With Advanced Solid Tumors
G. Shapiro, E. O'Mara, O. Laskin, Lan Gao +11 more
2021Clinical pharmacology in drug development23 citations
Semantic Scholar
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
C. Kollmannsberger, H. Hurwitz, L. Bazhenova, B. Cho +11 more
2022Targeted oncology20 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. D'Andrea×12
Invite
A. D'Andrea — researcher profile on SciRah
J. Cleary×6
Invite
J. Cleary — researcher profile on SciRah
B. Kochupurakkal×6
Invite
B. Kochupurakkal — researcher profile on SciRah
P. Konstantinopoulos×5
Invite
P. Konstantinopoulos — researcher profile on SciRah

×5

Invite

R. Plummer — researcher profile on SciRah

Invite

K. Do — researcher profile on SciRah

Invite

B. Wolpin — researcher profile on SciRah

Dipanjan Chowdhury×4

Invite

Dipanjan Chowdhury — researcher profile on SciRah

Constantia Pantelidou×4

Invite

Constantia Pantelidou — researcher profile on SciRah

U. Matulonis×4

Invite

U. Matulonis — researcher profile on SciRah

Invite

E. Swisher — researcher profile on SciRah

I. Díaz-Padilla×4

Invite

I. Díaz-Padilla — researcher profile on SciRah